SUN-627: an experimental immune-targeting drug being studied in progressive MS

What is being studied

SUN-627 is an oral drug that Sundance Biosciences describes as a brain-penetrant inhibitor of TYK2, an enzyme involved in immune signalling. A registered Phase 2a study compares two once-daily dose levels with placebo in adults with primary progressive or non-active secondary progressive MS. It chiefly measures safety over 16 weeks; it also measures drug exposure and neuroinflammation biomarkers.

Research stage

Testing whether it helps patients

The current listing is open to participants.

What we know so far

ClinicalTrials.gov lists the overall study and three US locations as open to participants, with an estimated October 2026 start and 20 planned participants. No results for NCT07840326 are posted. The listed status does not confirm actual start or dosing. The sponsor's mechanism description is not evidence of clinical benefit. Separately, the EU Clinical Trials Information System records SUN-627-MS201 (EUCT 2026-525817-29-00), a Phase 2a study in Finland. Finland authorised that study on 5 June 2026; its 18 June 2026 registry update listed recruitment as pending and showed no actual start date. This is the status shown in a registry record last updated on 18 June, not proof that recruitment or dosing has begun in practice. No MS201 results were shown in the reviewed record.

What this means for patients today

SUN-627 is an experimental study drug, not an available treatment. This registry record lists three US sites and no Greek site; current registry contacts give the study's eligibility details. The record does not establish benefit for symptoms or disability, or myelin repair. The separate Finnish MS201 record listed Finland only at its 18 June 2026 update; it does not establish a Greek study site or treatment access. The registry does not establish whether recruitment or dosing has actually begun.